EGFR and lung carcinoma: To identify targets that could be inhibited in combination with EGFR-specific TKIs to yield deeper growth inhibition in EGFR mutant lung cancer cell lines, Casas-Selves et al. [80] used a genome-wide shRNA screen and identified multiple components of the canonical Wnt pathway as contributors to the maintenance of NSCLC cells during EGFR inhibition.